Chi­na back­ers help bankroll a $100M mega-round as an in­flu­en­tial an­ti­body en­gi­neer read­ies tri­als

Kymab turned to some mar­quee names in the UK and the US for the mon­ey need­ed to es­tab­lish the com­pa­ny as a high-pro­file play­er in the world of an­ti­body cus­tomiza­tion over the past 6 years. But now the game plan for the next three years will be un­der­writ­ten by an ex­pand­ed syn­di­cate that in­cludes two new play­ers based in Chi­na, ex­tend­ing its net­work of back­ers in­to a glob­al loop.

The biotech has un­veiled a whop­ping $100 mil­lion round led by ORI Health­care Fund — found­ed by Si­mone (Hong Fang) Song, the for­mer chief of Gold­man Sachs’ Health­care Fund in Chi­na —  and the man­u­fac­tur­er Shen­zhen He­palink Phar­ma­ceu­ti­cal Com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.